Alogabat (example 8) is a GABAA α5 receptor positive allosteric modulators (PAMs) (extracted from patent WO2018104419A1).

3-Oxo-4,6-choladien-24-oic acid is an endogenous metabolite. 3-Oxo-4,6-choladien-24-oic acid exsists in the urine of patients with hepatobiliary disease.

2,8-Dihydroxyadenine, an endogenous metabolite, can cause the formation of urinary crystals and kidney stones. 2,8-Dihydroxyadenine can be used to diagnose adenine phosphoribosyltransferase (APRT) deficiency.

Sec61-IN-2 (A3) is a protein secretion inhibitor (extracted from patent WO2020176863).

Ezurpimtrostat (compound 2-2) is used for the study of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases (extracted from patent WO2020048694 A1).

4-Phenyl-7,8-dihydroxycoumarin is a coumarin derivative and can be used for bronchiectasiss research.

Gitoxin, a Na+/K+-ATPase inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably.

Ivospemin is an antineoplastic spermine analog.

Lenalidomide-C10-OH (6a) is an intermediate in the synthesis of INY-03-041.

Quercetin 3,3'-dimethyl ether possesses antioxidant acticity.

Sec61-IN-2 (A347) is a protein secretion inhibitor (extracted from patent WO2020176863).

Sophoramine ((-)-Sophoramine), an alkaloid, is a dehydro-derivative of Matrine.

Sucunamostat is an L-aspartic acid enteropeptidase inhibitor.

Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).

Yadanzioside M is a natural compound with anti-cancer activity.

D-(+)-Fucose is a nonmetabolizable analogue of l-arabinose. D-(+)-Fucose prevents growth of Escherichia coli B/r on a mineral salts medium plus l-arabinose by inhibiting induction of the l-arabinose operon. D-fucose is a potent inducer of beta-methylgalactoside permease (MGP).

Medifoxamine is a monoamine re-uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake.

(S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77).

Valethamate bromide is an ester and is a potent rapidly acting anticholinergic spasmolytic and musculotropic agent which accelerates labor by improving cervical dilation.

Elinzanetant is a neurokinin receptors antagonist used for the research of Schizophrenia.

Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.

Nilofabicin is an enoyl-(acyl-carrier protein) reductase (FabI) inhibitor. Nilofabicin had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

3,3'-Diethyloxacarbocyanine iodide is a microviscosity probe for micelles and microemulsions.

A2B receptor antagonist 2 (compound 18) is an adenosine receptor A2B antagonist, with Ki values of 2.30 μM, 6.8 μM and 3.44 μM for rA1, rA2A and hA2B, respectively.

Ludaterone is an antiandrogen agent, with potent antiandrogenic activity.

Mosliciguat is a guanylate cyclase activator.

Imifoplatin is a platinum-based agent belonging to the phosphaplatin family. Imifoplatin exhibits antineoplastic activity.

Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer.

NHE3-IN-2 is a Na+/H+ exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin).

(R)-BAY-899 is the R-enantiomer of BAY-899. BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC50s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively.